Suchergebnisse - "Gupta, Neeraj"

PubPharm (19)

1

Mobocertinib : Mechanism of action, clinical, and translational science

enthalten in: Clinical and translational science | 2024

von Hanley, M. | Camidge, D. | Fram, R. | +1

2

Clinical Pharmacology of Brigatinib : A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

enthalten in: Clinical pharmacokinetics | 2023

von Gupta, N. | Hanley, M. | Griffin, R. | +3

3

Response-Based Dosing for Ponatinib : Model-Based Analyses of the Dose-Ranging OPTIC Study

enthalten in: Clinical pharmacology and therapeutics | 2023

von Hanley, M. | Diderichsen, P. | Rich, B. | +5

4

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

enthalten in: Investigational new drugs | 2023

von Hanley, M. | Kerstein, D. | Tugnait, M. | +4

5

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

enthalten in: Journal of clinical pharmacology | 2023

von Hanley, M. | D'Arcangelo, M. | Felip, E. | +5

6

Population Pharmacokinetics of Mivavotinib (TAK-659), a Dual Spleen Tyrosine Kinase and FMS-Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies

enthalten in: Journal of clinical pharmacology | 2023

von Li, C. | Watson, K. | Wang, S. | +2

7

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer

enthalten in: Expert review of anticancer therapy | 2023

von Yang, J. | Zhou, C. | Jänne, P. | +18

8

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions : Exposure-Response Analyses of a Pivotal Phase I/II Study

enthalten in: Clinical pharmacology and therapeutics | 2022

von Gupta, N. | Largajolli, A. | Witjes, H. | +5

9

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase-positive non-small cell lung cancer

enthalten in: British journal of clinical pharmacology | 2022

von Gupta, N. | Hanley, M. | Sinha, V.

CommentOn: Br J Clin Pharmacol. 2022 Feb;88(4):1930-1934. - PMID 34545619

10

Assessment of Effects of Investigational TAK-931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors

enthalten in: Clinical pharmacology in drug development | 2022

von Zhou, X. | Diderichsen, P. | Gupta, N.